Lumenis Showcases Its Advanced CO2 Solutions for Throat Cancer With Transoral Laser Microsurgery at the AAO-HNSF Annual Meeting

YOKNEAM, ISRAEL--(Marketwired - Sep 21, 2014) - Lumenis Ltd. (NASDAQ: LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, showcases its novel CO₂ laser AcuPulse™ DUO, along with a wide range of fibers and accessories, at the Academy of Otolaryngology - Head and Neck Surgery (AAO-HNSF) 2014 Annual Meeting, which takes place September 21-24^th in Orlando, Florida. Lumenis exhibits at booth #829 throughout the meeting.

Tzipi Ozer-Armon, CEO of Lumenis, stated: "Our commitment to delivering the advanced and versatile ENT solutions for physicians and patients was the driving force behind the development of the AcuPulse DUO, our flagship platform for head and neck surgery. This advanced product solution perfectly embodies our mission of brininging better technologies for better patient care in the ENT domain. I am also pleased to say that thus far we have received outstanding feedback from surgeons regarding the performance of the AcuPulse DUO. Furthermore, as evident from mounting clinical data, this product significantly improves access to transoral laser microsurgery, or TLM, which can help preserve throat cancer patients' facial appearance and protect the ability to function normally."

Throat cancer is the second most common cancer in the upper aerodigestive tract, with over 12,000 new cases a year in the United States and nearly 3,000 annual deaths.¹ The use of chemotherapy, radiation therapy, or cold knife surgery in the treatment of transoral airway cancer is associated with complications. Alternatively, TLM offers low morbidity and excellent cure rates compared to chemoradiation.² Patients treated with TLM have no risk of radiation-associated side effects. Overall treatment and recovery time are faster than with radiation. Moreover, after receiving radiation as the first-line treatment, many patients may no longer be able to undergo minimally invasive procedures if the first round of radiation therapy is unsuccessful. The only option then is radical surgery, often requiring removal of the whole voice box, resulting in loss of voice. With TLM, the option of repeated minimally invasive surgery interventions and even radiation therapy remains, if necessary.

To help physicians and patients have better conversations about treatment options for throat cancer, Lumenis recently introduced a new patient education website, www.Throat-Cancer.com, where visitors can find disease information, an overview of the TLM procedure and videos with medical experts and patients sharing their insights about the condition.

AcuPulse DUO has a wide range of fibers and accessories that are tailored to patient needs and enhance surgeons' flexibility, and surgical capabilities to treat a broader range of clinical applications. The innovative MicroLase™ Fiber with Micro-G™ and Micro-H™ Otology Kits significantly reduce the cost per procedure since the fiber can be used up to 25 times and offers disposable tips. The superior design of the fiber allows sufficient laser energy transmission, enabling to get as close as possible to parity between the energy displayed on screen and the energy actually delivered to the patient. 

Lumenis' uncompromising commitment to improving the health and well-being of patients has led to the expansion of its technology outside the operating room and into outpatient treatment. With a strong emphasis on efficacy, patients can now get affordable yet personalized treatments without down time under local anesthesia. Office-based procedures allow the physicians to manage their time more efficiently and provide better care to their patients. All of the proven advantages of Lumenis' technology are being adopted in the convenience of the physicians' clinic.

Lumenis' Key Activities at the AAO-HNSF Annual Meeting
Sunday, September 21, 2014
11:30 am
Booth Presentation: "Fibers & Line of Site, When and Why?"
Led by Paul F. Castellanos, M.D., F.C.C.P., Associate Professor of Surgery, Director, University of Alabama at Birmingham Voice and AeroDigestive Center
Lumenis booth #829

Monday, September 22, 2014
6:30 am
Satellite Symposium: "Digital AcuBlade™ and the CO₂ Laser Treatment of T1 and T2 Laryngeal Cancer"
Led by Marc J. Remacle, M.D., Ph.D., Department of ORL and Head & Neck Surgery, University Hospital of Mont-Godinne, Belgium, and Abie Mendelsohn, M.D., Assistant Professor-in-Residence Director - Head & Neck Robotic Surgery Program Co-Chair - FPG Surgical Services Robotic Subcommittee, David Geffen School of Medicine at UCLA
Hyatt Regency Orlando, 9801 International Drive, Orlando, FL 32819
Coral Springs Room
To register, visit: http://information.lumenis.com/aao-hnsf-2014-e1

11:30 am
Booth Presentation: "Expanding your Range of Care: Office Procedures Utilizing the CO₂ Fiber"
Led by Joshua Scnhindler, M.D., Associate Professor and Medical Director, OHSU-Northwest Center for Voice and Swallowing, Oregon Health & Science University
Lumenis booth #829

3:00 pm
Instruction Course: "Transoral Endoscopic Head and Neck Surgery"
Led by Chris Holsinger, M.D., Professor of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center
Room 310B

Tuesday, September 23, 2014
12:00 pm
Booth Presentation: "Versatility by means of Fibers & Line of Site on a Single System"
Led by Marc J. Remacle, M.D., PhD, Department of ORL and Head & Neck Surgery, University Hospital of Mont-Godinne, Belgium
Lumenis booth #829

1:45 pm
Instruction Course: "Early Vocal Fold Cancer: A Practical Guide to TLM Cordectomy"
Led by Marc J. Remacle, M.D., PhD, Department of ORL and Head & Neck Surgery, University Hospital of Mont-Godinne, Belgium
Room 307CD

About Lumenis
Lumenis (NASDAQ: LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare.

For more information visit: www.lumenis.com

References:

1. Rubinstein M, Armstrong WB, Transoral Laser Microsurgery for Laryngeal Cancer: A Primer and Review of Last Dosimetry, 2011, Lasers Med Sci, 26:113-124.

2. Hinni ML, Salassa JR, Grant DG, Pearson BW, Hayden RE, Martin A, Christiansen H, Haughey BH, Nussenbaum B, Steiner W, Transoral Laser Microsurgery for Advanced
 Laryngeal Cancer, Arch Otolaryngol Head Neck Surg, 2007, 133(12):1198-204.